Newsletter



October 2, 2019

Human Metabolome Technologies, Inc. (Stock code: 6090, TSE Mothers)

HMT BioMedical, Inc. ("HMT-BM"), a subsidiary of Human Metabolome Technologies, Inc ("HMT") has signed a collaboration agreement with J-VPD, INC.

J-VPD, INC. provides clinical diagnostic testing services, as well as advanced medical devices and pharmaceuticals to more than 10 countries, with a primary focus on India through their subsidiary J-VPD Diagnostics India Private Limited.

The scope of this collaboration agreement is to offer laboratory testing services for research and clinical purposes, utilizing biomarkers *_1 for mental disorders and lifestyle-related diseases. At present, we will focus on the Indian market, which is sustaining a high economic growth, and striving for commercialization.

Mr. HASHIZUME Katsuhito, CEO of HMT-BM stated, "We sincerely hope that our biomarker testing service will have an impact on maintaining health and preventing diseases of people all over the world. This partnership will become a major stepping stone for us to contribute to healthcare in India."

HMT-BM has commenced the above contract services and will further expand its business in the future.

¾1 biomarker

A measurable indicator of the severity or presence of a medical condition

About Human Metabolome Technologies, Inc. (HMT)

HMT is a biotech venture founded in 2003, based on the research achievements attained at the Institute for Advanced Biosciences (IAB), Keio University, Japan. HMT provides capillary electrophoresis mass spectrometry-based metabolomics services for researchers from companies and public research institutions. HMT is currently working on the development of clinical tests that utilize biomarkers for objective assessment of specific diseases. The company was listed on TSE Mothers in December 2013, on the 10th anniversary of its founding.

About J-VPD, Inc. (J-VPD)

J-VPD is headquartered in Tokyo, Japan and Mr Yamada Tetsuji is the representative President. Its primary business scope includes international clinical laboratory testing business, sales of medical devices and pharmaceutical and quasi drugs, consulting services for hospital management and marketing services for medical-related companies.

Newsletter



Public Relations Inquiries
Human Metabolome Technologies, Inc.
Head of IR
Kenji Sasabe
TEL 03-3551-2180 FAX 03-3551-2181
invre1@humanmetabolome.com